OptimizeRx Corp. announced its financial results for the third quarter ended September 30, 2024, reporting revenue of $21.3 million. This represents a 30% increase compared to the same period in the prior year, demonstrating significant top-line growth.
The company's gross profit for the third quarter rose by 37% year-over-year to $13.4 million, achieving a gross margin of 63%. OptimizeRx also secured five new Dynamic Audience Activation Platform (DAAP) deals during the quarter, indicating traction with its key technology platform.
OptimizeRx updated its full-year 2024 guidance, expecting revenue to be between $88 million and $92 million, and Adjusted EBITDA to be between $8 million and $10 million. The company also reported paying down an additional $2.0 million of principal on its term loan since the end of the third quarter and was cash flow positive for the period.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.